Current adjuvants and new perspectives in vaccine formulation

References

• Wack A, Rappuoli R. Vaccinology at the beginning of the 21st Century. Curr. Opin. Immunol.17(4), 411–418 (2005).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov.2(9), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol.8(4), 279–289 (2008).
   PubMed Web of Science ®Google Scholar
• McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol.8, 37 (2010).
   PubMed Web of Science ®Google Scholar
• De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol.38(8), 2068–2071 (2008).
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol.9(4), 287–293 (2009).
   PubMed Web of Science ®Google Scholar
• Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine23(13), 1588–1595 (2005).
   PubMed Web of Science ®Google Scholar
• Ulanova M, Tarkowski A, Hahn-Zoric M, Hanson LA. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun.69(2), 1151–1159 (2001).
   PubMed Web of Science ®Google Scholar
• Kool M, Soullié T, van Nimwegen M et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med.205(4), 869–882 (2008).
   PubMed Web of Science ®Google Scholar
• Seubert A, Monaci E, Pizza M et al. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol.180(8), 5402–5412 (2008).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature453(7198), 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol.30(1), 23–32 (2009).
   PubMed Web of Science ®Google Scholar
• Allison AC, Byars NE. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods95(2), 157–168 (1986).
   PubMed Web of Science ®Google Scholar
• Higgins DA, Carlson JR, Van Nest G. Mf59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine14(6), 478–484 (1996).
   PubMed Web of Science ®Google Scholar
• Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. Mf59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol.6, 277–296 (1995).
   PubMedGoogle Scholar
• Podda A, Del Giudice G. Mf59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2(2), 197–203 (2003).
   PubMedGoogle Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N. Trial of 2009 influenza a (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med.361(25), 2424–2435 (2009).
   PubMed Web of Science ®Google Scholar
• Straus SE, Wald A, Kost RG et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins d and b: results of a placebo-controlled vaccine trial. J. Infect. Dis.176(5), 1129–1134 (1997).
   PubMed Web of Science ®Google Scholar
• Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine17(22), 2769–2778 (1999).
   PubMed Web of Science ®Google Scholar
• McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis.184(10), 1331–1335 (2001).
   PubMed Web of Science ®Google Scholar
• Childers NK, Miller KL, Tong G, Llarena JC, Greenway T, Ulrich JT. Adjuvant activity of monophosphoryl lipid a for nasal and oral immunization with soluble or liposome-associated antigen. Infect. Immun.68(10), 5509–5516 (2000).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Jonas S, Althaus B, Finkel B, Gluck R. Immunogenicity and protectivity of a new liposomal hepatitis a vaccine. Vaccine15(11), 1209–1213 (1997).
   PubMed Web of Science ®Google Scholar
• Calcagnile S, Zuccotti GV. The virosomal adjuvanted influenza vaccine. Expert Opin. Biol. Ther.10(2), 191–200 (2010).
   PubMed Web of Science ®Google Scholar
• Taneichi M, Ishida H, Kajino K et al. Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J. Immunol.177(4), 2324–2330 (2006).
   PubMed Web of Science ®Google Scholar
• Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine14(10), 982–986 (1996).
   PubMed Web of Science ®Google Scholar
• Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillen G, Aguilar JC. Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen. Mol. Immunol.42(3), 289–294 (2005).
   PubMed Web of Science ®Google Scholar
• Tay EH, Garland S, Tang G et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the asia-pacific region. Int. J. Gynaecol. Obstet.102(3), 275–283 (2008).
   Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367, 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. Immunological activity of chitin and its derivatives. Vaccine2(1), 93–99 (1984).
   PubMedGoogle Scholar
• Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine16(20), 2039–2046 (1998).
   PubMed Web of Science ®Google Scholar
• McNeela EA, Mills KH. Manipulating the immune system: humoral versus cell-mediated immunity. Adv. Drug Deliv. Rev.51(1–3), 43–54 (2001).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from quillaja saponaria molina cortex. J. Immunol.146(2), 431–437 (1991).
   PubMed Web of Science ®Google Scholar
• Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine27(33), 4388–4401 (2009).
   PubMed Web of Science ®Google Scholar
• Morein B, Hu KF, Abusugra I. Current status and potential application of ISCOMS in veterinary medicine. Adv. Drug Deliv. Rev.56(10), 1367–1382 (2004).
   PubMed Web of Science ®Google Scholar
• Wikman M, Friedman M, Pinitkiatisakul S et al. General strategies for efficient adjuvant incorporation of recombinant subunit immunogens. Vaccine23(17–18), 2331–2335 (2005).
   PubMed Web of Science ®Google Scholar
• Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs7(9), 1475–1482 (1998).
   PubMedGoogle Scholar
• Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet364(9443), 1411–1420 (2004).
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol.5(10), 987–995 (2004).
   PubMed Web of Science ®Google Scholar
• Koyama S, Coban C, Aoshi T, Horii T, Akira S, Ishii KJ. Innate immune control of nucleic acid-based vaccine immunogenicity. Expert Rev. Vaccines8(8), 1099–1107 (2009).
   PubMed Web of Science ®Google Scholar
• Baldridge JR, Crane RT. Monophosphoryl lipid a (MPL) formulations for the next generation of vaccines. Methods19(1), 103–107 (1999).
   PubMed Web of Science ®Google Scholar
• Di Paolo D, Lenci I, Cerocchi C et al. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl. Int.23(11), 1105–1112 (2010).
   PubMed Web of Science ®Google Scholar
• Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev. Vaccines8(12), 1663–1679 (2009).
   PubMed Web of Science ®Google Scholar
• Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs68(3), 359–372 (2008).
   PubMed Web of Science ®Google Scholar
• Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin. Biol. Ther.8(2), 235–247 (2008).
   PubMed Web of Science ®Google Scholar
• Bojang KA, Olodude F, Pinder M et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine23(32), 4148–4157 (2005).
   PubMed Web of Science ®Google Scholar
• Reed S, Lobet Y. Tuberculosis vaccine development; from mouse to man. Microbes Infect.7(5–6), 922–931 (2005).
   PubMed Web of Science ®Google Scholar
• Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol21(5), 244–249 (2005).
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov.5(6), 471–484 (2006).
   PubMed Web of Science ®Google Scholar
• Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther.7(11), 1731–1737 (2007).
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 gag protein conjugated to a TLR 7/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8+ T cell responses. J. Immunol.174(12), 7676–7683 (2005).
   PubMed Web of Science ®Google Scholar
• Huang SJ, Hijnen D, Murphy GF et al. Imiquimod enhances IFN-γ production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J. Invest. Dermatol.129(11), 2676–2685 (2009).
   PubMed Web of Science ®Google Scholar
• Heath AW. Cytokines as immunological adjuvants. Pharm. Biotechnol.6, 645–658 (1995).
   PubMedGoogle Scholar
• Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect. Immun.71(8), 4780–4788 (2003).
   PubMed Web of Science ®Google Scholar
• Verastegui E, Barrera JL, Zinser J et al. A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. Int. J. Immunopharmacol.19(11–12), 619–627 (1997).
   PubMed Web of Science ®Google Scholar
• Hadden JW. T-cell adjuvants. Int. J. Immunopharmacol.16(9), 703–710 (1994).
   PubMed Web of Science ®Google Scholar
• Goldstein AL, Low TL, McAdoo M et al. Thymosin α1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc. Natl Acad. Sci. USA74(2), 725–729 (1977).
   PubMed Web of Science ®Google Scholar
• Peng Y, Chen Z, Yu W et al. Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol. Int.32(10), 1265–1271 (2008).
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Gaziano R et al. Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood103(11), 4232–4239 (2004).
   PubMed Web of Science ®Google Scholar
• Garaci E, Favalli C, Pica F et al. Thymosin α 1: From bench to bedside. Ann. NY Acad. Sci.1112, 225–234 (2007).
   PubMed Web of Science ®Google Scholar
• Garaci E, Thymosin α1: a historical overview. Ann. NY Acad. Sci.1112, 14–20 (2007).
   PubMed Web of Science ®Google Scholar
• Naylor PH, Hadden JW. T cell targeted immune enhancement yields effective T cell adjuvants. Int. Immunopharmacol.3(8), 1205–1215 (2003).
   Google Scholar
• Brennan FR, Dougan G. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies. Vaccine23(24), 3210–3222 (2005).
   PubMed Web of Science ®Google Scholar
• Sesardic D, Dobbelaer R. European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine22(19), 2452–2456 (2004).
   PubMed Web of Science ®Google Scholar
• Robert Edelma. An overview of adjuvant use. In: Vaccine Adjuvants, Preparation Methods and Research Protocols. Derek T, O’Hagan (Eds). Humana Press, Totowa, NJ, USA, 1–28 (2000).
   Google Scholar
• Allison AC, Byars NE. Immunological adjuvants: desirable properties and side-effects. Mol. Immunol.28(3), 279–284 (1991).
   PubMed Web of Science ®Google Scholar